Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374146 | 1.00 | CNR1 (0.59) | CNR1SLC6A3FPR2RAB9APOLB | |
| SCHEMBL5950236 | 0.87 | MEN1 (0.49) | CNR1SLC6A3FPR2RAB9AGRIK1 | |
| SCHEMBL6373231 | 0.87 | CNR1 (0.60) | CNR1FPR2RAB9AGRIK1KMT2A | |
| SCHEMBL6378865 | 0.87 | CNR1 (0.60) | CNR1FPR2RAB9AGRIK1KMT2A | |
| SCHEMBL6373252 | 0.87 | FPR2 (0.73) | CNR1FPR2RAB9ALMNAKMT2A | |
| SCHEMBL5632770 | 0.87 | FPR2 (0.73) | CNR1FPR2RAB9ALMNAKMT2A | |
| SCHEMBL3568468 | 0.87 | FPR2 (0.73) | CNR1FPR2RAB9ALMNAKMT2A | |
| SCHEMBL5950360 | 0.84 | FPR2 (0.48) | CNR1SLC6A3FPR2RAB9AGRIK1 | |
| SCHEMBL5950200 | 0.84 | MEN1 (0.58) | CNR1FPR2RAB9ALMNAKMT2A | |
| SCHEMBL28041623 | 0.81 | CNR1 (0.60) | CNR1SLC6A3RAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1341755-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002048099-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GMBH (DE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | CNR1 6/4885SLC6A3 4720/4885FPR2 766/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | CNR1 2/4885SLC6A3 4807/4885FPR2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.